Naltrexone: Clinical Overview
Naltrexone is a mu-opioid receptor antagonist FDA-approved for treating alcohol use disorder at 50 mg daily and opioid use disorder at 25-50 mg daily (or 380 mg monthly injection), requiring patients to be completely opioid-free for 7-10 days before initiation to prevent precipitated withdrawal. 1
FDA-Approved Indications
Alcohol Use Disorder
- Standard dose: 50 mg orally once daily 1
- Demonstrated efficacy in placebo-controlled trials up to 12 weeks
- Must be part of comprehensive treatment including behavioral therapy and community support
- Alternative dosing for supervised administration: 100 mg every other day or 150 mg every third day 1
Opioid Use Disorder
- Initial dose: 25 mg once, then 50 mg daily if no withdrawal occurs 1
- Monthly injection (Vivitrol 380 mg) available for both alcohol and opioid dependence 2
- Most effective in highly motivated populations (e.g., healthcare professionals) 2
- Limited success in less motivated patient groups 2
Critical Contraindications and Precautions
Absolute Requirements Before Starting
Patients MUST be opioid-free for minimum 7-10 days (short-acting opioids) or up to 2 weeks (buprenorphine/methadone) 1. This is non-negotiable—initiating naltrexone in opioid-dependent patients will precipitate severe withdrawal that can manifest for up to 2 weeks when switching from buprenorphine or methadone 1.
Naloxone Challenge Test
Perform if any doubt about opioid-free status 1:
IV route:
- Inject 0.2 mg naloxone, observe 30 seconds
- If no withdrawal, inject 0.6 mg, observe 20 minutes
Subcutaneous route:
- Administer 0.8 mg naloxone, observe 20 minutes
Interpretation: If ANY withdrawal signs appear (nausea, vomiting, sweating, pupillary dilation, yawning, craving, abdominal cramps, anxiety, muscle aches), DO NOT start naltrexone. Repeat challenge in 24 hours 1.
Cannot Use Naltrexone If:
- Patient requires opioid analgesics for pain management (naltrexone blocks all opioid effects) 2
- Patient showing clinical withdrawal signs
- Urine contains opioids 1
Monitoring Requirements
Liver function tests are mandatory 2:
- Baseline LFTs before initiation
- Repeat every 3-6 months during treatment
- Naltrexone causes hepatocellular injury at supratherapeutic doses (>50 mg) 2
- Risk increases with extended dosing intervals using higher single doses 1
Common Adverse Effects
From alcohol use disorder trials (most common, >2% incidence) 1:
- Nausea (10%)
- Headache (7%)
- Dizziness (4%)
- Nervousness (4%)
- Fatigue (4%)
- Insomnia (3%)
- Vomiting (3%)
Important safety note: Depression and suicidal ideation occur at similar rates in naltrexone and placebo groups (0-15% vs 0-17% for depression; 0-1% vs 0-3% for suicide attempts), but naltrexone does NOT reduce suicide risk in these populations 1.
Off-Label Low-Dose Use
Low-dose naltrexone (LDN, typically 4.5 mg daily) is increasingly used off-label for chronic pain, autoimmune conditions, and other disorders 3, 4, 5. However, current evidence does not support routine clinical use—most positive findings from uncontrolled studies were not replicated in placebo-controlled trials 3.
A 2025 evaluation in veterans showed minimal benefit (average pain score reduction of only -0.83) 4. LDN may have a pragmatic role only in treatment-resistant cases where standard therapies have failed, with clear explanation of its experimental status 3.
Key Clinical Pitfalls
Never start naltrexone without confirming adequate opioid-free period—this causes severe precipitated withdrawal 1
Do not use in patients requiring opioid pain management—naltrexone blocks therapeutic opioid effects 2
Naltrexone alone is insufficient—it only works as part of comprehensive treatment with behavioral therapy, psychosocial support, and compliance monitoring 1
Patients discontinuing naltrexone face increased overdose risk due to decreased opioid tolerance 2
Higher single doses (>50 mg) carry greater hepatotoxicity risk, particularly with extended dosing schedules 1
Patient selection matters—naltrexone works best in motivated patients with stable living environments, employment, family support, and those previously on low-dose methadone 2